Rutten F F, Ploeg R J, McDonnell J, Cohen B
Institute for Medical Technology Assessment, Erasmus University Rotterdam, The Netherlands.
Transplantation. 1993 Oct;56(4):854-8. doi: 10.1097/00007890-199310000-00015.
University of Wisconsin (UW) solution is now commonly used as a single-flush solution during multiorgan procurement for effective preservation of all intraabdominal organs including the kidney. Many kidneys from single kidney donors are still preserved in Eurocollins solution and the question is whether preservation in UW solution is more cost-effective. A European randomized multicenter trial was organized by the Department of Surgery of Leiden University in close cooperation with Eurotransplant to study the efficacy of UW solution as compared with EC solution. On the basis of this trial we found that at three months after transplant 92.4% of the patients in the UW group had a functioning graft in comparison with 88.4% in the EC group (similar figures after one year were 88.2% and 82.5%, P approximately 0.04), while health care expenditure during these first three months was on average US$ 700 lower for the UW group than for the EC group, taking into account the price difference in the preservation fluids. The long-term benefits of using UW solution as compared with EC solution were conservatively estimated at US$ 7000 per patient reflecting the additional expenses for dialysis in the EC group. We concluded that the extra costs of using UW solution instead of EC solution (US$ 230 per kidney) can be easily earned back within three months and that the long-term savings of such a strategy are considerable. Moreover, the health status of patients in the UW group is expected to be better on the average than in the EC group. Simply reacting to the price tag of the UW solution may be penny-wise but pound-foolish.
威斯康星大学(UW)溶液目前常用于多器官获取过程中的单次冲洗溶液,以有效保存包括肾脏在内的所有腹腔内器官。许多来自单肾供体的肾脏仍保存在欧洲柯林斯溶液中,问题在于保存在UW溶液中是否更具成本效益。莱顿大学外科系与欧洲器官移植组织密切合作组织了一项欧洲随机多中心试验,以研究UW溶液与欧洲柯林斯(EC)溶液相比的疗效。基于该试验,我们发现移植后三个月,UW组92.4%的患者移植肾有功能,而EC组为88.4%(一年后的类似数字分别为88.2%和82.5%,P约为0.04),同时考虑到保存液的价格差异,UW组在前三个月的医疗保健支出平均比EC组低700美元。与EC溶液相比,使用UW溶液的长期效益保守估计为每位患者7000美元,这反映了EC组的透析额外费用。我们得出结论,使用UW溶液而非EC溶液的额外成本(每肾230美元)可在三个月内轻松收回,且该策略的长期节省相当可观。此外,预计UW组患者的平均健康状况优于EC组。仅仅对UW溶液的价格标签做出反应可能是因小失大。